Literature DB >> 8300352

Induction of c-fos by prostaglandin F2 alpha in human ciliary smooth muscle cells.

J D Lindsey1, H D To, R N Weinreb.   

Abstract

PURPOSE: To evaluate the induction of the proto-oncogene c-fos in cultured human ciliary muscle cells by prostaglandin F2 alpha (PGF2 alpha) by 17-phenyltrinor-PGF 2 alpha.
METHOD: Human ciliary muscle cells were grown to confluency in monolayer cell culture, placed in medium containing 1% fetal bovine serum for 5 days, treated by addition of PGF2 alpha or the trinor derivative, fixed, and then immunocytochemically stained using an antibody to c-Fos, the protein product of the translation of c-fos.
RESULTS: After treatment with either agonist, the mean induction score (proportion of brightly immunostained nuclei) increased to a maximal level during the first hour and returned to basal levels 4 to 8 hours after treatment. Increasing the agonist concentration increased the maximal level, but had no effect on the time course of the response. The dose responses after 1 hour of treatment with PGF2 alpha or 17-phenyltrinor-PGF2 alpha increased similarly between 1.6 x 10(-9) M and 2 x 10(-7) M. When treated with 1 x 10(-6) M of either agonist, however, the induction was half that obtained at 2 x 10(-7) M.
CONCLUSION: Exposure of ciliary smooth muscle cells to either PGF2 alpha or 17-phenyltrinor-PGF2 alpha induces an immediate early gene expression response that is similar to c-Fos induction in other cell systems. These results establish the basis for future investigations evaluating the potential role of c-fos induction in mediating the effects of PGF2 alpha on uveoscleral outflow.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8300352

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

Review 1.  Effects of prostaglandin analogues on aqueous humor outflow pathways.

Authors:  Nelson S Winkler; Michael P Fautsch
Journal:  J Ocul Pharmacol Ther       Date:  2013-12-20       Impact factor: 2.671

Review 2.  [Suprachoroidal minimally invasive glaucoma surgery : Procedures and clinical outcome].

Authors:  C Erb
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

3.  Enhancement of scleral macromolecular permeability with prostaglandins.

Authors:  R N Weinreb
Journal:  Trans Am Ophthalmol Soc       Date:  2001

4.  Travoprost in the management of open-angle glaucoma and ocular hypertension.

Authors:  Philippe Denis; David Covert; Anthony Realini
Journal:  Clin Ophthalmol       Date:  2007-03

5.  First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2007-09

Review 6.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways.

Authors:  Xiaohong Li; Fen He; B'Ann T Gabelt; Yun Wang; Suping Cai; Juanhui Cao; Ning Fan; Paul L Kaufman; Xuyang Liu
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

8.  Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells.

Authors:  Yu-Qing Lan; Chi Zhang; Jian-Hui Xiao; Ye-Hong Zhuo; Hui Guo; Wei Peng; Jian Ge
Journal:  Mol Vis       Date:  2009-09-26       Impact factor: 2.367

Review 9.  An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy.

Authors:  Derrick S Fung; Jess T Whitson
Journal:  Clin Ophthalmol       Date:  2014-03-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.